Compare Incyte Corporation (INCY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TotalEnergies SE — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while TotalEnergies SE trades at $86.42 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 8.4× Incyte Corporation's market cap, and TotalEnergies SE pays a 4.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and TotalEnergies SE for 90 Days on average.
| INCY | TTE | |
|---|---|---|
Market Cap | $22.85B | $191.82B |
Volume | 1,927,029 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $129.93 | $93.60 |
52-Week Low | $83.80 | $57.39 |
Typical Hold Time | 33 Days | 90 Days |
Enterprise Value | $18.35B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
TotalEnergies (TTE) trades at $87.25, up 3.59% today, with a bearish technical signal but strong fundamentals including a low P/E of 10.77 and robust cash flow. Recent earnings beat expectations in Q1 and Q2 2026, while the company announced a $10 billion investment in Argentina and plans for dividend growth through 2030, signaling strategic expansion.
The outlook is positive with analyst consensus at Buy and a $95.33 price target, though risks include declining revenue trends and geopolitical exposure. Upside potential hinges on execution of growth initiatives and energy price stability, while investor sentiment remains supported by shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
